Clark Estates Inc. NY Sells 75,123 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Clark Estates Inc. NY lessened its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 39.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 115,000 shares of the company's stock after selling 75,123 shares during the period. GE HealthCare Technologies comprises 2.0% of Clark Estates Inc. NY's portfolio, making the stock its 11th largest holding. Clark Estates Inc. NY's holdings in GE HealthCare Technologies were worth $10,793,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. boosted its position in shares of GE HealthCare Technologies by 17.0% during the first quarter. B. Riley Wealth Advisors Inc. now owns 7,404 shares of the company's stock valued at $673,000 after buying an additional 1,074 shares during the last quarter. California State Teachers Retirement System lifted its stake in GE HealthCare Technologies by 2.2% during the 1st quarter. California State Teachers Retirement System now owns 682,116 shares of the company's stock valued at $62,011,000 after acquiring an additional 14,800 shares during the period. Hancock Whitney Corp boosted its holdings in shares of GE HealthCare Technologies by 1.6% during the 1st quarter. Hancock Whitney Corp now owns 17,595 shares of the company's stock valued at $1,600,000 after acquiring an additional 279 shares during the last quarter. iA Global Asset Management Inc. grew its stake in shares of GE HealthCare Technologies by 4.5% in the first quarter. iA Global Asset Management Inc. now owns 42,786 shares of the company's stock worth $3,890,000 after acquiring an additional 1,843 shares during the period. Finally, XML Financial LLC raised its holdings in shares of GE HealthCare Technologies by 6.9% during the first quarter. XML Financial LLC now owns 3,357 shares of the company's stock valued at $305,000 after purchasing an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC traded up $0.49 during midday trading on Wednesday, reaching $83.00. 1,807,505 shares of the company were exchanged, compared to its average volume of 3,075,193. The stock has a market cap of $37.92 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 2.96 and a beta of 1.24. The business's fifty day moving average is $88.19 and its two-hundred day moving average is $83.61. GE HealthCare Technologies Inc. has a one year low of $66.39 and a one year high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. During the same quarter in the prior year, the firm earned $0.99 EPS. The business's revenue was up .9% on a year-over-year basis. As a group, analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be issued a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a dividend yield of 0.17%. This is a boost from GE HealthCare Technologies's previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies's dividend payout ratio is 3.30%.

Insider Activity

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares of the company's stock, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

GEHC has been the topic of several research reports. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. Stifel Nicolaus lifted their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a report on Monday, September 30th. Evercore ISI increased their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. BTIG Research upgraded GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a research report on Wednesday, September 18th. Finally, Redburn Atlantic raised GE HealthCare Technologies to a "strong-buy" rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, GE HealthCare Technologies presently has an average rating of "Moderate Buy" and an average target price of $94.36.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.